GlassScriptPhysician profile
James J Yeh
NPI 1144411885
$5,592.96
in general payments reported to CMS, 2019-2025
48 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $337 · 2021: $474 · 2022: $643 · 2023: $787 · 2024: $1,069 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,863 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.38 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $536.98 | 2019-2025 | Tecentriq, Polivy |
| Janssen Biotech, INC. | $393.50 | 2019-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $382.52 | 2019-2025 | |
| Celgene Corporation | $353.49 | 2019-2025 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $316.97 | 2019-2025 | Trodelvy |
| Exelixis INC. | $264.12 | 2019-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $261.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $248.75 | 2019-2025 | Tagrisso, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $213.70 | 2019-2025 | Opdivo |
| Genzyme Corporation | $207.10 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $192.28 | 2020-2025 | Xpovio |
| Emd Serono, INC. | $191.45 | 2021-2024 | |
| Seagen INC. | $173.40 | 2022-2023 | Adcetris, Tukysa, Tivdak |
| Regeneron Healthcare Solutions, INC. | $163.40 | 2019-2024 | Libtayo |
| Lilly USA, LLC | $149.46 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.